M
Mozart Therapeutics
Focuses on developing novel immune engagers
About Mozart Therapeutics
Mozart Therapeutics, a privately held biopharmaceutical firm, was established in Seattle in June 2020 to engineer therapies for autoimmune and inflammatory conditions. The company's scientific foundation rests on the discoveries of its scientific co-founders from Stanford University: Mark M. Davis, Ph.D., K. Christopher Garcia, Ph.D., and Calvin Kuo, M.D., Ph.D. Their research identified a crucial network of immune cells, known as regulatory CD8 T cells (CD8 Tregs), that are essential for maintaining immune balance by identifying and eliminating cells that cause autoimmune disease. The company is led by President and CEO Katie Fanning, a biotech industry veteran with over 35 years of experience, including roles as CEO at Nohla Therapeutics and COO at VentiRx.
The company's business model is centered on the discovery, development, and eventual commercialization of these specialized therapeutics. Mozart has secured substantial funding to advance its pipeline, raising a total of $80 million through a Series A financing. The initial round of $55 million in October 2021 was led by ARCH Venture Partners and Sofinnova Partners, with participation from major pharmaceutical venture arms like Eli Lilly & Company, MRL Ventures Fund (Merck), and Leaps by Bayer. An additional $25 million was raised in June 2023 from new investors, including Pfizer Ventures and AbbVie Ventures.
Mozart's core product is a portfolio of CD8 Treg Modulators, which are engineered proteins designed to restore the normal function of the body's regulatory CD8 T cell network. Unlike broad immunosuppressants, these modulators are designed to selectively target the root cause of the autoimmune response without compromising the entire immune system. Their lead candidate, MTX-101, is a bispecific autoimmune checkpoint inhibitor that targets KIR and CD8 to restore the function of CD8 Tregs. This therapeutic is initially being developed for autoimmune gastrointestinal diseases, such as celiac disease, Crohn's disease, and ulcerative colitis. The company anticipated filing an Investigational New Drug (IND) application for MTX-101 and initiating Phase 1 human clinical trials in early 2024.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2023 | $25M | $275M | AbbVie · UPMC Enterprises · Pfizer Ventures | ↗ |
| SERIES AOther financing | Oct 2021 | $55M | $220M | Sofinnova Partners · Altitude Life Science Ventures · Alexandria Venture Investments · MRL Ventures | — |
Growth signals
Latest recorded traffic for Mozart Therapeutics is 2K monthly website visits, down 16.7% over the last three months. Mozart Therapeutics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Mozart Therapeutics in the Seattle ecosystem
The Mozart Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
ARCH Venture Partners
Sofinnova Partners
Altitude Life Science Ventures
Alexandria Venture Investments
MRL Ventures
Bayer
Eli Lilly
AbbVie
UPMC Enterprises- PVPfizer Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mozart Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mozart Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









